1. Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)
- Author
-
Jianlin Geng, Xuejun Li, Zhiqiang Ning, Haixiang Cao, Weihong Song, Xin Gao, Zunhai Zhou, Yangang Wang, He Yao, Hanqing Cai, Lian Guo, Wei Li, Xinsheng Li, Gangyi Yang, Zhiguang Zhou, Desi Pan, Fuyan Shi, Hongmei Li, Weiping Jia, Yanjun Liu, Linong Ji, Hui Fang, Haoming Tian, Shuying Li, Yancheng Xu, Qifu Li, Kuanzhi Liu, Lu Xianping, Tao Yang, Qiuhe Ji, Qing Su, and Wenbo Wang
- Subjects
Agonist ,chemistry.chemical_classification ,medicine.medical_specialty ,Multidisciplinary ,business.industry ,medicine.drug_class ,Peroxisome proliferator-activated receptor ,Type 2 diabetes ,010502 geochemistry & geophysics ,medicine.disease ,Placebo ,01 natural sciences ,Gastroenterology ,chemistry ,Chiglitazar ,Internal medicine ,medicine ,Clinical endpoint ,In patient ,business ,0105 earth and related environmental sciences ,Glycemic - Abstract
Chiglitazar (Carfloglitazar) is a novel non-thiazolidinedione (TZD) structured peroxisome proliferator-activated receptor (PPAR) pan-agonist that has shown promising effects on glycemic control and lipid regulation in patients with type 2 diabetes in previous clinical studies. This randomized phase 3 trial aimed to compare the efficacy and safety of chiglitazar with placebo in patients with type 2 diabetes with insufficient glycemic control by strict diet and exercise alone. Eligible patients were randomly assigned to receive chiglitazar 32 mg (n = 167), chiglitazar 48 mg (n = 166), or placebo (n = 202) once daily. The primary endpoint was the change in glycosylated hemoglobin A1c (HbA1c) at week 24 with superiority of chiglitazar over placebo. The results showed that both chiglitazar 32 and 48 mg resulted in significant and clinically meaningful reductions in HbA1c, and placebo-adjusted estimated treatment differences at week 24 for chiglitazar 32 and 48 mg were −0.87% (95% confidential interval (CI): −1.10 to −0.65; P
- Published
- 2021